

## Effect of *Kabdeen* in *Warm-e-Kabid Vairoosi* (viral hepatitis)

M M H Siddiqui,\* Asia Sultana,\*\* and M Y Siddiqui\*

\*Department of Moalejat, A K Tibbiya College A M U Aligarh 202 002, Uttar Pradesh; \*\*Department of Moalejat, Faculty of Medicine, Jamia Hamdard, New Delhi 110 062  
E-mail: drhaque@rediffmail.com

Received 2 August 2004; revised 11 March 2005

The therapeutic evaluation of a polyherbal non-pharmacopoeial Unani formulation *Kabdeen* in 50 patients of *Warm-e-Kabid Vairoosi* (viral hepatitis) revealed an over all clinical improvement in about 75.17 % at the end of 3<sup>rd</sup> week and 87.54 % at the end of 6<sup>th</sup> week, while 42.1 % improvement was observed in cases of hepatitis B. Out of 19 hepatitis B positive cases, 8 cases showed Australian antigen test negative. It was also observed during the study that the test drug not only restores the normal functioning of the liver but also has no side effects.

**Keywords:** Viral hepatitis, *Warm-e-Kabid Vairoosi*, *Kabdeen*, Antiinflammatory Activity Hepatoprotective Activity, Antioxidants activity, Antiviral Activity, Unani Medicine, Nephrotoxicity

**IPC Int. Cl.<sup>7</sup>:** A61K35/78, A61P1/04, A61P1/06, A61P1/08, A61P1/14, A61P1/16, A61P7/06, A61P31/02, A61P41/00, A61P43/00

Even though the horizon of medical science is expanding with acquisition of more and more knowledge about diseases and their management, the wish of man for a healthy living still remains unfulfilled. However, with the advent of advanced diagnostic tools and techniques, now the fighting strategy of man against diseases has drastically undergone, a sort of metamorphosis. This is true especially for the management of many tropical diseases. Viral hepatitis is one of the important tropical diseases responsible for significant morbidity and mortality in developing countries including India.

Liver, the largest gland of the body, receives blood supply from both systemic and portal routes and thus is at a high risk to infections by viruses via the dual routes. The list of hepatotropic viruses is very long, basically they are either RNA (Fig. 1) or DNA (Fig. 2) and share the ability to target the liver cells.

*Warm-e-Kabid Vairoosi* (Viral Hepatitis) is a systemic infection that affects liver predominantly, causing a significant morbidity and mortality. The first reference to jaundice is ascribed to Hippocrates. According to the ancient Unani physicians, it was referred to as an abnormal state of humour, caused by excessive intake of meat, alcohol, oily and spicy food, sweet preparations, improper diet and increased production of *Safra* (Bile). However, as the advanced

microbiological researches have produced enormous information and knowledge about the etiology of diseases, several serologically and structurally distinct viruses, which are transmitted either horizontally or vertically, have been regarded responsible for this disease. The discovery of serological markers has made it possible to make out exactly the specific type of hepatitis. Usually viral hepatitis is caused by one or more of the five viral agents i.e. Hepatitis-A (HAV), Hepatitis-B (HBV), Hepatitis-C (HCV), Hepatitis-D (HDV) and Hepatitis-E (HEV). A sixth agent Hepatitis-G (HGV), has been discovered but its role in the ailment is yet to be established. Among all, Hepatitis-A is considered to be highly infectious while Hepatitis-B as one of the most grievous viral infections known so far. Efforts are on in all medical sciences to evolve drug for combating this dreadful disease. In Unani System of Medicine, plants as a whole or their parts are extensively used for the cure of liver derangements<sup>1-4</sup>.

### Methodology

The study was conducted on 50 patients in Ajmal Khan Tibbiya College Hospital, Aligarh Muslim University, Aligarh during a period of two years. Detailed history regarding illness and possible source of infection, physical examination, liver function test and Hepatitis panel was made out for diagnostic and prognostic purposes. Kidney functions were also

\* Corresponding author

assessed to rule out any possible nephro-toxicity. *Kabdeen* [(a polyherbal non-pharmacopoeial formulation), Table 1] was given in a dose of 10 ml 8 hourly for a period of 6 weeks. Results were analyzed

statistically using the non-parametric chi-square test and the paired sample test.

## Results and Discussion

Several herbo-animo-minerals used in traditional systems of medicine have been identified as being effective in hepatic disorders. Most of them are useful in maintaining liver functions and subsiding hepatic toxicity of different nature because of being hepatoprotective. The test drug produced striking hepatoprotective effect on the patients of viral hepatitis in terms of subsiding its signs and symptoms (Table 2) and brought down the level of serum bilirubin (Table 3 & Fig. 3), marker enzymes of liver function, because elevation of marker enzymes like Serum Transaminases (ALT & AST), Serum Alkaline Phosphatase, Lactate dehydrogenase (Table 4 & Fig. 4-5) and Prothrombin time are important indications of liver damage (Table 5 & Fig. 6)<sup>5-7</sup>.

The dramatic improvement in clinical features and speedy biochemical recovery may be attributed to various constituents of *Kabdeen* e.g. *Mako* (*Solanum nigrum* Linn.), *Kasni* (*Cichorium intybus* Linn.), *Shahatra* (*Fumaria officinalis* Linn.), *Branjasif* (*Aquilaria agallocha* Roxb.) and *Gul-e-Ghafis* (*Gentiana dahurica* Fisch. Syn. *G. olivieri* Griseb.) which have choleric and cholagogue properties and a strong hepatoprotective effect<sup>8-10</sup>. These drugs also facilitate flow of bile by producing contractions in bile canaliculi and thus help in correcting the intra-

Table 1—Composition of Kabdeen in each 5 ml

| Constituents     | Botanical name                        | Quantity (in mg) |
|------------------|---------------------------------------|------------------|
| Balchar          | <i>Valeriana jatamansi</i> Jones      | 80               |
| Branjasif        | <i>Achillea mellifolium</i> Linn.     | 160              |
| Bekh-Kasni       | <i>Cichorium intybus</i> Linn.        | 80               |
| Tukhm-e-Bathua   | <i>Chenopodium album</i> Linn.        | 80               |
| Tukhm-e-Khayaren | <i>Cucumis sativus</i> Linn.          | 80               |
| Tukhm-e-Kasni    | <i>Cichorium intybus</i> Linn.        | 160              |
| Tukhm-e-Kasoos   | <i>Cuscuta reflexa</i> Roxb.          | 80               |
| Chiraita shireen | <i>Swertia chirata</i> Karst.         | 40               |
| Khoolanjan       | <i>Alpinia galanga</i> Willd.         | 80               |
| Reward Chini     | <i>Rheum emodi</i> Wall. ex Meissn.   | 40               |
| Shahatra         | <i>Fumaria officinalis</i> Linn.      | 80               |
| Satar Farsi      | <i>Zataria multiflora</i> Boiss.      | 80               |
| Ushba Maghrabi   | <i>Smilax aspera</i> Linn.            | 80               |
| Uood-e-Hindi     | <i>Aquilaria agallocha</i> Roxb.      | 80               |
| Kasondi          | <i>Cassia occidentalis</i> Linn.      | 80               |
| Gul-e-Tesu       | <i>Butea monosperma</i> (Lam.) Kuntze | 160              |
| Gul-e-Surkh      | <i>Rosa damascena</i> Mill.           | 40               |
| Gul-e-Ghafis     | <i>Gentiana olivieri</i> Griseb.      | 160              |
| Gul-e-Nelofar    | <i>Nymphaea alba</i> Linn.            | 80               |
| Mako             | <i>Solanum nigrum</i> Linn.           | 160              |
| Nar Mushk        | <i>Mesua ferrea</i> Linn.             | 80               |
| Qand Safaid      | Sugar                                 | 4.5Gm            |

Table 2—Incidence of different signs/symptoms in three phases of the study

| Symptoms/Signs       | 0 day |      | End of 3 <sup>rd</sup> week |       | Sample size = 50<br>End of 6 <sup>th</sup> week |       |
|----------------------|-------|------|-----------------------------|-------|---|-------|
|                      | No    | %    | No                          | %     | No  | %     |
|                      |       |      | Improvement                 |       | Improvement                                     |       |
| Jaundice             | 48    | 96.0 | 06                          | 87.5  | 00.0  | 100.0 |
| Anorexia             | 46    | 92.0 | 01                          | 97.8  | 00.0  | 100.0 |
| Nausea               | 31    | 62.0 | 00                          | 100.0 | 00.0  | 100.0 |
| Vomiting             | 07    | 14.0 | 00                          | 100.0 | 00.0  | 100.0 |
| Fever                | 19    | 38.0 | 04                          | 79.0  | 00.0  | 100.0 |
| Aversion for smoking | 17    | 34.0 | 03                          | 82.4  | 00.0  | 100.0 |
| Pain in abdomen      | 27    | 54.0 | 02                          | 92.6  | 00.0  | 100.0 |
| Muscle cramps        | 20    | 40.0 | 06                          | 70.0  | 00.0  | 100.0 |
| Arthralgia           | 05    | 10.0 | 05                          | 100.0 | 02.0  | 60.0  |
| Distaste             | 29    | 58.0 | 01                          | 96.5  | 00.0  | 100.0 |
| Loss of weight       | 10    | 20.0 | 09                          | 90.0  | 08.0  | 20.0  |
| Dark urine           | 46    | 92.0 | 05                          | 89.1  | 00.0  | 100.0 |
| Dark stool           | 24    | 48.0 | 00                          | 100.0 | 00.0  | 100.0 |
| Icterus              | 48    | 96.0 | 06                          | 87.5  | 00.0  | 100.0 |
| Hepatomegaly         | 24    | 48.0 | 06                          | 75.0  | 01.0  | 95.8  |
| Splenomegaly         | 07    | 14.0 | 01                          | 85.7  | 00.0  | 100.0 |
| Lymph-adenopathy     | 01    | 02.0 | 01                          | 100.0 | 01.0  | 00.0  |
| Palmer erythema      | 03    | 06.0 | 00                          | 100.0 | 00.0  | 100.0 |

hepatic cholestatic jaundice. *Cassia occidentalis* Linn. (*Kasondi*) having antiinflammatory properties helps in subsiding the inflammatory process in the liver. *Mako* and *Kasni* normalize raised the levels of Serum Transaminases, Serum Alkaline Phosphatase and Lactate de-Hydrogenase. Moreover, *Mako* prevents the formation of collagenous substances in hepatic architecture and helps in preventing dreadful complications like hepatic cirrhosis. *Swertia chirata* Karst. (*Chiraita shireen*) containing an alkaloid andrographolide possesses hepatoprotective and antiviral properties<sup>9-12</sup>. Similarly, *Tukhm-e-Kasoos* (*Cuscuta reflexa* Roxb.) contains a specific protein, which also has antiviral properties. *Kasni* possesses antioxidant properties and prevents the damage to DNA by free radicals<sup>13</sup>. It also inhibits susceptibility of plasma lipo-proteins to oxidation causing free radical damage. It is likely that during the replication of DNA, these drugs might interfere with the faithful copying of DNA to new daughter DNA by virtue of interference in DNA polymerase enzyme which negates the Australian antigen test (Table 5 & Fig.7).

## Conclusion

*Kabdeen* revealed an over all clinical improvement in patients of viral hepatitis 75.17 percent (at the end of 3<sup>rd</sup> week) and 87.54 percent (at the end of 6<sup>th</sup> week), while 42.1 percent improvement was observed in cases of hepatitis B. Out of Nineteen hepatitis B positive cases, eight cases showed Australian Antigen Test negative. It was also observed during the study that the test drug not only restored the normal functioning of the liver but also showed no side effects. The large variation between treated and controlled titer value of C-reactive protein is obvious. It is an acute phase protein, which increases many folds in any inflammatory condition after 12 hour of inflammation, and it comes to normal very quickly after the recovery from infection or inflammation. The active constituent colchicine is not reported to commonly cause liver damage<sup>14</sup>. On the contrary, it improves liver function in primary biliary cirrhosis<sup>15</sup>. It may cause nephrotoxicity only on acute poisoning.

Table 3—Weekly effect of *Kabdeen* on Mean Serum Bilirubin in mg percentage

| Duration (in weeks)        | Before treatment |      |      | After treatment |      |      |      | P value  |
|----------------------------|------------------|------|------|-----------------|------|------|------|----------|
|                            | 0                | 1    | 2    | 3               | 4    | 5    | 6    |          |
| Serum Bilirubin (Total)    | 8.04             | 8.24 | 3.44 | 1.69            | 1.09 | 1.04 | 1.01 | P<0.0001 |
| Serum Bilirubin (Direct)   | 4.51             | 3.72 | 1.59 | 0.80            | 0.51 | 0.48 | 0.49 | P<0.0001 |
| Serum Bilirubin (Indirect) | 4.51             | 4.52 | 1.85 | 0.89            | 0.58 | 0.56 | 0.52 | P<0.0001 |

Table 4—Weekly effect of *Kabdeen* on (Mean Serum Transaminases in I.U & Mean Serum Alkaline Phosphatase in K-Au/ml)

| Duration in weeks            | Before treatment |       |       | After treatment |        |       |        | P value  |
|------------------------------|------------------|-------|-------|-----------------|--------|-------|--------|----------|
|                              | 0                | 1     | 2     | 3               | 4      | 5     | 6      |          |
| Aspartate Transaminase (AST) | 92.71            | 93.41 | 55.40 | 39.39           | 31.44  | 28.30 | 24.46  | P<0.001  |
| Alanine Transaminase (ALT)   | 85.76            | 63.78 | 48.40 | 37.78           | 28.90  | 24.00 | 21.22  | P<0.0001 |
| Serum Alkaline Phosphats     | 18.79            | 18.12 | 12.36 | 10.80           | 09.68  | 08.88 | 07.21  | P<0.0001 |
| Lactate Dehydrogenase (LDH)  | 251.56           | —     | —     | —               | 169.04 | —     | 160.64 | P<0.001  |

Table 5—Effect of *Kabdeen* on Mean Prothrombin time in seconds (n = 50) & Australia Antigen (HBsAg) n = 19

| Duration (in weeks)                             | Before treatment |       | After treatment           |       | P value  |
|---|------------------|-------|---------------------------|-------|----------|
|   | 0                | 4     | 4                         | 6     |          |
| Prothrombin Time (Patients)                     | 19.06            | 15.38 | 14.46                     | 13.24 | P<0.0001 |
| Prothrombin Time (Standard)                     | 13.24            | 13.24 | 13.24                     | 13.24 | P<0.0000 |
| Australia Antigen Test 19 Cases (38 %) Positive | —                |       | 8 Cases (42.1 %) Negative |       |          |




Fig. 1- Schematic diagram of RNA virus




Fig. 2- Schematic diagram of DNA virus




Fig. 3- Showing effect of *Kabdeen* on Mean Serum Bilirubin in mg %




Fig. 4- Showing effect of *Kabdeen* on Mean S.AST, S.ALT and S. Alk. Phosph.




Fig. 5- Showing weekly effect of *Kabdeen* on Mean Lactate Dehydrogenase




Fig. 6- Showing effect of *Kabdeen* on Mean Prothrombin Time




Fig. 7- Showing effect of *Kabdeen* on Australia Antigen

**References**

- 1 Akbar M, Meezan-ut-Tib, (Taraqqi Urdu Bureau, New Delhi), 1992,155-156.
- 2 Antaki D, Tazkarah ulul Albab, (Azhari Press, Egypt), 1,1930, 220-221.
- 3 Arzani A, Tibb-e-Akbar, (Matba Naval Kishore, Lucknow), 2, 1956, 8-11.
- 4 Acron C J, Millar C, Hoffman S K and Lyle W M, Viral hepatitis – A review, *Optometry & Vision Science*, University of Waterloo, Ontario, Canada, 72(10) (1995), 763-769.
- 5 Subramonium A, Evans D A, Rai Shekharan S and Pushpanagdan P, Hepato-protective activity of *Trichopus zeylanicus* extract against paracetamol induced hepatic damage in rats, *Indian J Exp Biol*, 36 (1998), 385-389.
- 6 Varley H, Practical clinical Biochemistry, 3<sup>rd</sup> edition, (New York Enter Science Books, Inc.) 1964, 908.
- 7 Christopher R W, Edward Ian, A D Bouchier, Davidson's Principles and Practice of Medicine, ed 6, (Churchill Livingstone, U K), 1992, 488-496
- 8 Jindal M N, Paul V K and Patel N B, Some pharmacological action of aqueous and alcoholic extracts of *C. intybus* Linn., *Indian J Pharmacol*, 7 (1975), 104.
- 9 Subramonium A and Pushpangadan P, Development of Phytomedicines for liver diseases, *Indian J Pharmacol*, 31 (1999), 166-175.
- 10 Satyawati GV, Raina M K and Sharma M, Medicinal plants of India, ICMR New Delhi, 1, 1976, 64-227, 2, 242-351.
- 11 Dymock W, Warden C J H and Hooper D, Pharmacographia Indica-A history of the principal drugs of vegetable origin, Reprinted by Institute of Health and Tibbi Research (Pakistan), 3, 1893, 65-67, 3, 114-155.
- 12 Rastogi R P and Mehrotra B N, Compendium of Indian Medicinal plants, CDRI, Lucknow & PID, New Delhi, 4, 1995, 7, 4,36-59, 4,59-184.
- 13 Sultana S, Parwaiz S, Iqbal M and Athur M, Crude extracts of hepatoprotective plants, *Solanum nigrum* and *Cichorium intybus* inhibits free radical mediated DNA damage, *J Ethnopharmacology*, 45 (1995),189-192.
- 14 Warnes T W, Colchicine in primary biliary cirrhosis Aliment, *Pharmacol Ther*, 5 (1991), 321-379
- 15 Roberts L J and Morrow J D, Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of Gout, in Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10<sup>th</sup> ed, Editors: Hardman J.G & Gilman A G, (McGraw-Hill, New York), 2001, p 720